UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer

Clinical & translational oncology, 2022-12, Vol.24 (12), p.2432-2440

2022

Volltextzugriff (PDF)

Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

Clinical & translational oncology, 2024-03, Vol.26 (3), p.732-738

2024

Volltextzugriff (PDF)

Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation

Journal of the National Comprehensive Cancer Network, 2017-11, Vol.15 (11), p.1310-1315

2017

Volltextzugriff (PDF)

Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization

Urologic oncology, 2015-04, Vol.33 (4), p.179-186

2015

Volltextzugriff (PDF)

Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB

World journal of clinical oncology, 2014-05, Vol.5 (2), p.86-92

2014

Volltextzugriff (PDF)

Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?

Clinical & translational oncology, 2011-07, Vol.13 (7), p.451-459

2011

Volltextzugriff (PDF)

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

The lancet oncology, 2022-03, Vol.23 (3), p.362-373

2022

Volltextzugriff (PDF)

Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

Frontiers in immunology, 2023-04, Vol.14, p.1156603-1156603

2023

Volltextzugriff (PDF)

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

Clinical & translational oncology, 2023-03, Vol.25 (3), p.768-775

2023

Volltextzugriff (PDF)

Genotyping the Host in the Battle Against Cancer

European urology focus, 2016-12, Vol.2 (6), p.640-641

2016

Volltextzugriff (PDF)

Abstract 5288: Mechanisms of resistance to FGFR inhibitors in urothelial cancer cell lines and patients harboring FGFR3 alterations and strategies to overcome it

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5288-5288

2020

Volltextzugriff (PDF)

Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9586-TPS9586

2021

Volltextzugriff (PDF)

Abstract 4475: Targeting c-MET and MAPK pathway in metastatic castration-resistant prostate cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4475-4475

2019

Volltextzugriff (PDF)

Dynamic profiling in patients with metastatic clear cell renal cell carcinoma (mRCC) undergoing first-line treatment with cabozantinib: A sub-exploratory analysis from CABOPRE trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.474-474

2024

Volltextzugriff (PDF)

Prognostic impact of fibroblast growth factor receptor (FGFR) genomic alterations and outcomes in patients with metastatic urothelial

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.537-537

2022

Volltextzugriff (PDF)

Proteomic profiling of peritoneal fluid-derived exosomes as a tool for the identification of prognostic markers in advanced ovarian carcinomas

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17561-e17561

2023

Volltextzugriff (PDF)

Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016–01)

Gynecologic oncology, 2024-12, Vol.191, p.233-239

2024

Volltextzugriff (PDF)

Clinical outcome in terms of survival and treatment response of patients with metastatic urothelial carcinoma harboring FGFR alterations compared to wild-type tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17042-e17042

2020

Volltextzugriff (PDF)

Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.546-546

2022

Volltextzugriff (PDF)

Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17582-e17582

2020

Volltextzugriff (PDF)

CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS4603-TPS4603

2018

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer

MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer

Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy

Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation

Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization

Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB

Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

Genotyping the Host in the Battle Against Cancer

Abstract 5288: Mechanisms of resistance to FGFR inhibitors in urothelial cancer cell lines and patients harboring FGFR3 alterations and strategies to overcome it

Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

Abstract 4475: Targeting c-MET and MAPK pathway in metastatic castration-resistant prostate cancer

Dynamic profiling in patients with metastatic clear cell renal cell carcinoma (mRCC) undergoing first-line treatment with cabozantinib: A sub-exploratory analysis from CABOPRE trial

Prognostic impact of fibroblast growth factor receptor (FGFR) genomic alterations and outcomes in patients with metastatic urothelial

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

Proteomic profiling of peritoneal fluid-derived exosomes as a tool for the identification of prognostic markers in advanced ovarian carcinomas

Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016–01)

Clinical outcome in terms of survival and treatment response of patients with metastatic urothelial carcinoma harboring FGFR alterations compared to wild-type tumors

Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial

Single nucleotide polymorphisms (SNPs) as predictors of efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)

CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC)

Suchergebnisse filtern